Jun 9 2011
Inter Press Service examines how "[m]oves by developed nations such as the United States to tighten intellectual property laws are threatening to limit production and distribution of generic drugs, which experts say have been and will remain key in the prevention and treatment of HIV/AIDS and currently account for 80 percent of HIV/AIDS treatment." The article looks at how negotiations over the outcome document of this week's U.N. High Level Meeting on AIDS, as well as bilateral trade agreements between developed and developing nations, are proceeding and could affect the Trade-Related Aspects of Intellectual Property Rights agreement (Whitman, 6/7).
 This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.
|
Triptans better at relieving migraine pain than recently marketed and more expensive drugs